• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600671.SS
Share

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Stocks

CN¥ 21.61Last Updated 30.09.2026

Issuer Rating

3/7
Performance

Poor

Risk

Limited

Recommendation

Sell

Market Cap

CN¥ 395.81M

CN¥ 21.61
Key Takeaways

Risk factor

Sufficiently resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, a company founded in 1958 and based in Hangzhou, China, operates a multifaceted business primarily focused on the pharmaceutical sector. Through its various subsidiaries, the company specializes in both the production and distribution of medicines throughout China. Its extensive product range includes the manufacturing and sale of a diverse array of pharmaceuticals and health-related goods. These encompass various dosage forms such as tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, and soft capsules, as well as a selection of health foods. Beyond finished products, Hangzhou TianMuShan is also involved in the trade of raw materials like menthol and peppermint oil. The company also offers a comprehensive selection of traditional Chinese medicine, including prepared formulas, individual herbal pieces, and fresh herbs. Furthermore, it provides specialized medical services such as custom decoction preparation and delivery, herbal slicing and powder grinding, and traditional Chinese medicine diagnosis and treatment. In addition to its core pharmaceutical activities, the enterprise has diversified into other ventures, including software development, remote health management solutions, commercial property administration, food services, and internet information businesses.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.10.2026 09:19

Twelve people were killed in an attack on the Riyadh airport

10.10.2026 16:01

What's Important in Small-Cap Stocks: Risks Associated with Webull, Levi's Outlook, and Vaxcyte's Success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

10.10.2026 06:47

Moderna hits four-year high as NYT reports U.S. cancer vaccine effort

10.10.2026 04:58

Palantir shares hit a new high: Barclays followed Goldman in recommending a buy

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026